Disc Medicine, Inc. , a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.
Disc Medicine stock last closed at $59.82, down 0.78% from the previous day, and has increased 23.93% in one year. It has overperformed other stocks in the Biotechnology industry by 0.73 percentage points. Disc Medicine stock is currently +94.09% from its 52-week low of $30.82, and -12.96% from its 52-week high of $68.73.
At the moment, there are 34.77M IRON shares outstanding. The market cap of IRON is $2.08B. In the past 24 hours, 179,000 IRON shares were traded.
How to Buy Disc Medicine Stock
Wondering how to invest in Disc Medicine stock? Here's how.
Figure out where to buy Disc Medicine stock: You need to pick a stock brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you choose where to buy Disc Medicine stock.
Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
Deposit money your brokerage account: Choose your method of payment and add your details.
Research Disc Medicine stock: The Disc Medicine ticker symbol is IRON. Is Disc Medicine stock a good investment? Should you buy shares of IRON? How do IRON's underlying business fundamentals look? Do top analysts think Disc Medicine is a good buy? Why has IRON's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if IRON is a good stock to buy).
Make your IRON buy order: Decide if you will purchase IRON shares at the current market price or use a limit order to purchase IRON shares at a specific price.
Watch your IRON position: Create a watchlist to important updates regarding your new investment in Disc Medicine shares.
Step 1: Figure out where to buy Disc Medicine stock
You need a brokerage account to access the NASDAQ market and buy IRON stock.
A brokerage account is an investment account that allows you to buy and sell a variety of investments, including stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best brokerage. Here's why:
Invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
Access to world markets: From Technology to Utilities, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by creating an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open a brokerage account
Now that you've picked your brokerage, the next step is to fill out some personal info so you can buy IRON stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Disc Medicine stock
After you have figured out the best place to buy Disc Medicine stock, it's very important to evaluate their stock before you buy, so you actually wrap your head around the risk as well as the upside.
Overview of key IRON info
IRON Price
$59.82
1w %
-1.55%
1y %
23.93%
5y %
-44.35%
P/E
-13.38x
P/B
3.39x
P/S
N/A
PEG
N/A
Revenue
$0.00
Earnings
-$145.39M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$2.08B
Next Earnings
Nov 6, 2025
Next Dividend
N/A
Fundamentals of Disc Medicine
WallStreetZen was created to help everyday investors do more accurate fundamental analysis in less time.
There are more short-term assets than long-term liabilities on the IRON balance sheet.
Total IRON debt is lower than 5 years ago, relative to shareholder equity.
IRON has a low debt to equity ratio of 0.08.
IRON has cash burn of 135556000. It has enough cash and short-term investments to cover this for at least one year.
There are more short-term assets than short-term liabilities on the IRON balance sheet.
IRON has $649.97M in cash and short term investments. This is sufficient to cover its annual cash burn of $135.56M.
Is it a good time to buy IRON stock, according to analysts?
Out of 6 sell side analysts who give ratings on IRON, the consensus analyst rating on IRON is a Strong Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
Most Recent IRON Analyst Upgrades/Downgrades
Kristen Kluska, a top 3% analyst from Cantor Fitzgerald maintains IRON with a strong buy rating and raises their IRON price target from $99.00 to $132.00, on Mar 18, 2025.
Cantor Fitzgerald's Kristen Kluska raised their price target on Disc Medicine (NASDAQ: IRON) by 33.3% from $99 to $132 on 2025/03/18. The analyst maintained their Strong Buy rating on the stock.
According to Kluska, Disc Medicine is set to submit a new medication application in 2H 2025 for bitopertin, an oral GlyT1 inhibitor, for the treatment of EPP (Erythropoietic Protoporphyria) and XLP (X-Linked Protoporphyria).
These rare heme illnesses cause patients to suffer from crippling agony whenever they are exposed to sunshine or artificial light, the analyst told readers.
After previously estimating $430M in U.S. revenues, Kluska said they now predict a peak of $900M in 2035.
Footnotes
Bitopertin is an investigational drug that acts as a GlyT1 inhibitor. It was initially developed to address symptoms of schizophrenia by modulating glutamatergic signaling in the brain. However, clinical trials for this purpose yielded disappointing results, leading to a shift in its focus.
A GlyT1 inhibitor is a type of drug that blocks the glycine transporter 1 protein. GlyT1 is responsible for regulating glycine levels in the brain by removing excess glycine from synapses.
EPP is a condition caused by a deficiency in the enzyme ferrochelatase, leading to an accumulation of protoporphyrin in red blood cells, plasma, and skin.
XLP is a similar condition caused by mutations in the ALAS2 gene, which leads to increased activity of an enzyme involved in heme production.
No, Disc Medicine doesn't provide an income stream by paying out dividends.
What others are saying about IRON
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Make your IRON buy order
You have two primary order types:
Market order: A market order is an order to buy or sell a stock at the best price on the market. Market orders are generally fine.
Limit order: A limit order allows you to buy or sell a stock at a specific price (or better). If you want to ensure you're buying or selling at an exact dollar amount limit, place a limit order.
Hit the Open Trade button and your broker will place your order.
If you require additional assistance buying stocks on eToro, watch the how to video below:
How much does it cost to buy one Disc Medicine share?
As of Sep 12, 2025, it costs $59.82 to buy one share of Disc Medicine stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.167 shares of IRON.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.